Emcure Pharmaceuticals

Prolong Pharmaceuticals, LLC, based in South Plainfield, NJ, is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for complex diseases, including ischemia, hypoxia within stroke, sickle cell disease, and cystic fibrosis. With a leadership team experienced in biotechnology and a pioneering approach to PEGylation, Prolong aims to meet critical unmet medical needs through its cutting-edge biopharma solutions. The company's flagship product, PP-007 Sanguinate, employs a novel PEGylated technology to restore homeostasis by delivering oxygen to hypoxic tissues and facilitating improved perfusion while reducing inflammation. Prolong Pharmaceuticals is committed to advancing healthcare through groundbreaking therapies targeting severe and life-threatening conditions, with a strong focus on addressing the global health issue of stroke. Generated from the website

Nanotech Pharmaceutical is a cutting-edge biotechnology company based in Hillsborough, NJ. Specializing in the development of advanced nanomedicines, the company is dedicated to revolutionizing the field of pharmaceuticals through innovative research and technology. With a focus on precision medicine and targeted drug delivery, Nanotech Pharmaceutical is committed to improving patient outcomes and advancing the future of healthcare. Their team of experts works tirelessly to create novel solutions for complex medical challenges, setting new standards in the industry. Generated from their business information

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. The company s specialized sales force markets Abelcet, Oncaspar, Adagen and Depocyt in North America. In addition, it also receives royalties on sales of Peg-Intron, which is marketed by Schering-Plough Corporation, and Macugen, which is marketed by OSI Pharmaceuticals and Pfizer. The company s product-driven strategy includes a drug development program that leverages its proprietary technologies that includes a next-generation PEGylation platform that utilizes linkers designed to release compounds at a controlled rate. Internal research and development efforts are complemented with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. Enzon Pharmaceuticals is headquartered in Bridgewater, N.J.